Abstract
The high number of infections caused by resistant bacteria shows an urgency for new antimicrobials. For Tuberculosis, this situation is no different. Caused mainly by the bacillus Mycobacterium tuberculosis, this is the infectious disease that kills the most in the world and, in 2017, caused 1.3 million deaths. Because of that, this project aims at the in vitro and in vivo study and also …